All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Dr Kutikov on Therapeutic Approaches in Urothelial Cancer Requiring Cystectomy

May 5th 2024

Alexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.

Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC

May 5th 2024

Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).

Nadofaragene Firadenovec Demonstrates Durable 5-Year Activity in NMIBC

May 5th 2024

Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003.

UGN-102 With/Without TURBT Produces Similar DOR and DFS in Newly Diagnosed and Recurrent NMIBC

May 5th 2024

UGN-102 with/without TURBT displayed meaningful and similar DFS and DOR rates in newly diagnosed and recurrent low-grade intermediate-risk NMIBC.

Dr Wang on the Role of Active Surveillance in Patients With Renal Masses

May 4th 2024

Katherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.

Dr Meeks on Harnessing Innovation in Bladder Cancer

May 4th 2024

Joshua J. Meeks, MD, PhD, discusses effectively implementing recent therapeutic advances across the disease continuum of bladder cancer.

PSMA-PET Plus Multi-Parametric MRI Aids Detection of Clinically Significant Prostate Cancer

May 4th 2024

18F-DCFPyL PSMA-PET imaging plus multi-parametric MRI improved the detection of clinically significant prostate cancer in low- and high-risk men on active surveillance.

Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC

May 4th 2024

Enzalutamide alone and with leuprolide led to greater rates of undetectable PSA levels vs leuprolide alone in castration-sensitive prostate cancer.

Dr Shore on the Importance of a Multidisciplinary Team in Urologic Oncology

May 3rd 2024

Neal Shore, MD, FACS, discusses the importance of a multidisciplinary team in light of recent developments in urologic oncology.

Apalutamide/ADT Demonstrates 100% Biochemical RFS Rate in High-Risk Prostate Cancer

May 3rd 2024

Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.

Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

May 3rd 2024

Outcome improvements with lutetium Lu 177 vipivotide tetraxetan vs ARPI change favored prior treatment with abiraterone vs enzalutamide in mCRPC.

18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer

May 3rd 2024

18F-PSMA-1007 PET/CT generated superior locoregional staging results vs multiparametric MRI in patients with prostate cancer.

Extended Lymphadenectomy Shows No DFS, OS Benefit During Radical Cystectomy in Urothelial Cancer

May 3rd 2024

Concurrent radical cystectomy and extended lymph node dissection did not show benefit vs standard lymph node dissection in muscle invasive urothelial cancer.

TAR-200 Leads to Durable Responses in Bacillus Calmette–Guérin-Unresponsive NMIBC

May 3rd 2024

TAR-200 displayed a high complete response rate in Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer.

HIFU Proves Noninferior to Radical Prostatectomy in Localized Prostate Cancer

May 3rd 2024

High-intensity focused ultrasound produced noninferior salvage treatment-free survival vs radical prostatectomy in localized prostate cancer.

Cretostimogene Monotherapy Elicits Durable CRs in High-Risk NMIBC

May 3rd 2024

Cretostimogene grenadenorepvec elicited durable responses in high-risk BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.

NXC-201 Receives Orphan Drug Designation in the European Union for Multiple Myeloma

May 3rd 2024

The CAR T-cell therapy NXC-201 has received orphan drug designation from the European Commission for patients with multiple myeloma.

Phase 2 Trial Closure Clears a Path for Accelerated Development of Stenoparib in Ovarian Cancer

May 3rd 2024

A phase 2 trial of stenoparib in advanced recurrent ovarian cancer has been closed early to enable a follow-on trial with FDA regulatory intent.

Florida Cancer Specialists & Research Institute Calls for Reform in Value-Based Oncology Care Programming

May 3rd 2024

Florida Cancer Specialists & Research Institute, LLC is calling for reform in value-based oncology care modeling.

Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection

May 3rd 2024

Rebecca Klisovic, MD, discusses 4 case studies of patients who presented with varying types of myelofibrosis and the appropriate treatment avenues for each patient.